Pinar is a technology transactions attorney with a specialized practice at the intersection of biotechnology and artificial intelligence. She helps life sciences and technology companies—from innovative startups to publicly traded leaders—structure, negotiate, and close complex deals involving intellectual property, data, and cutting-edge emerging technologies.

Drawing upon a Ph.D. in biophysics and years of experience managing intellectual property portfolios in areas such as gene sequencing, gene therapy, personalized medicine, bioinformatics, and AI/ML, Pinar partners with clients to address novel legal and regulatory challenges. She is recognized annually by Best Lawyers in America since 2020 for her work in Technology Law and Mergers and Acquisitions.

Her work includes development, collaboration, license, supply, and software agreements; IP acquisitions and licensing; IP due diligence and portfolio analysis; M&A, joint ventures and strategic alliances—often involving AI-enabled tools for drug discovery, diagnostics, therapeutics and other biotech applications. Representative matters range from structuring AI integrated R&D partnerships to advising on commercialization strategies for data driven diagnostics.

Pinar leads firm-wide initiatives serving clients in the AI/ML space and is an active speaker and author on emerging issues, with recent engagements covering AI-assisted drug discovery, governance of AI in healthcare, and regulatory trends for AI-enabled medical devices.

In addition to her active practice, Pinar is passionate about helping develop future intellectual property leaders, currently teaching Technology Transactions at Stanford Law School.